Willington Fruit Farm

Main Menu

  • Home
  • Outdoor market
  • Consumer demand
  • Food processing firm
  • Profit on produce
  • Wholesalers profit

Willington Fruit Farm

Header Banner

Willington Fruit Farm

  • Home
  • Outdoor market
  • Consumer demand
  • Food processing firm
  • Profit on produce
  • Wholesalers profit
Profit on produce
Home›Profit on produce›BioNTech Shares Jump As COVID Vaccine Boosts Profits From Earlier Estimates

BioNTech Shares Jump As COVID Vaccine Boosts Profits From Earlier Estimates

By Marsha A. Jones
August 9, 2021
0
0


BioNTech actions (BNTX) – Get a report jumped on Monday after the COVID-19 vaccine manufacturer’s second-quarter financial results exceeded consensus estimates from Wall Street analysts.

The German health care biotech company posted a profit of $ 12.67 per share from a loss of 45 cents per share in the previous year quarter.

Revenue reached $ 6.24 billion from $ 49 million.

Analysts polled by FactSet expected earnings of $ 8.87 per share on revenue of $ 3.83 billion.

“To address the ongoing pandemic, we are expanding the supply of our COVID-19 vaccine to more than 100 countries and regions around the world, including improving access to low and middle income countries,” said the general manager Ugur Sahin in a statement.

BioNTech shares at last check jumped 12% to $ 437. The stock is trading around its 52 week high, which is eight times its 52 week low set in early September.

The company claims to have shipped more than a billion doses worldwide in six months.

BioNTech says several clinical trials are underway, aimed at expanding the authorization of its COVID vaccine for use in children aged 6 months to 11 years and for healthy pregnant women.

The company and its vaccine partner, Pfizer (PFE) – Get a report, say a booster has the potential to preserve the highest level of efficacy and that clinical booster trials will begin this month.

BioNTech expects to be able to produce three billion doses of the vaccine by the end of 2021 with capacity expanded to four billion doses by 2022.

Aside from the vaccine, the company says its oncology program is progressing as well.

“We have been able to advance several oncology programs on various technology platforms that are now entering advanced stage testing, providing the potential to introduce a series of product candidates to the market in the years to come,” said Sahin.


Related posts:

  1. Latest coronavirus: Canada’s central bank to permanently adopt hybrid work model for staff
  2. Fear of obesity fuels $ 3.3 billion Pepsi juice deal
  3. Noodle is targeting another ed-tech market: non-degree courses
  4. In Epic vs. Apple Court Fight, a victory for application developers

Archives

  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021

Categories

  • Consumer demand
  • Food processing firm
  • Outdoor market
  • Profit on produce
  • Wholesalers profit

Recent Posts

  • McCain Foods buys crop analysis tools from agricultural data firm Resson
  • A year later, the Nikiski market offers a community center for farmers and creators
  • Vijay Mallya pursues attempts to overturn bankruptcy order in UK court
  • Aleph Farms Hires Head of Regulatory Affairs Pre-Global Commercialization
  • Is Medical Properties Trust a good dividend stock? (NYSE:MPW)